Category

• Legal1
• Products1

Organizations

• Bausch + Lomb66
• Eyes On Eyecare47
• Alcon, Inc.44
• American Optometric Association35
• Harrow29
• Glaukos26
• Regeneron23
• Topcon Healthcare23
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Products2
• Retina2
• AMD1
• DME1
• FDA1
• Fda Approval1
• Biosimilar1
• Diabetic Retinopathy1
• Injections1
• Lawsuit1

• Organizations: Celltrion, Inc✕

Clear all

Products

FDA approves Celltrion's Eylea bisoimilar

EYDENZELT (aflibercept-bvoa) is indicated for patients with wet AMD, macular edema following RVO, DME, and DR.

Legal

Regeneron files lawsuit against potential Eylea biosimilar

Company alleges Celltrion’s CT-P42 biosimilar poses a direct threat to its patented technology.